Gilead Sciences IncGILD:NSQ

101.81
1.605 / 1.55 %
8.51m
27.39%
0.7833
Close in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Mar 06 2015 21:15 GMT.

Consensus recommendation

As of Feb 28, 2015, the consensus forecast amongst 27 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy11
Outperform11
Hold4
Underperform1
Sell0
No opinion0

Research Reports

Ford Investor Services, Inc.

Share price forecast

The 23 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 120.00, with a high estimate of 159.00 and a low estimate of 84.00. The median estimate represents a 16.04% increase from the last price of 103.42. View Full Financials

High+56.2 %159.00
Med+17.9 %120.00
Low-17.5 %84.00

Dividends

Historical dividend information is not available for Gilead Sciences Inc. View Full Financials

Div growth (TTM)--
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Feb 03, 2015, Gilead Sciences, Inc. reported 4th quarter 2014 earnings of 2.43 per share. This result exceeded the 2.22 consensus of the 24 analysts covering the company and exceeded last year's 4th quarter results by 1.88.
The next earnings announcement is expected on Apr 20, 2015. View Full Interim Financials

Average growth rate+58.49 %

Gilead Sciences, Inc. reported annual 2014 earnings of 8.09 per share on Feb 03, 2015. View Full Annual Financials

Average growth rate+76.71 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

Gilead Sciences Inc. had 4th quarter 2014 revenues of 7.31bn. This bettered the 6.72bn consensus of the 22 analysts covering the company. This was 21.06% above the prior year's 4th quarter results. View Full Interim Financials

Average growth rate+26.12 %

Gilead Sciences Inc. had revenues for the full year 2014 of 24.89bn. This was 122.20% above the prior year's results. View Full Annual Financials

Average growth rate+39.71 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.